omeprazole has been researched along with Cystic Fibrosis in 16 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Omeprazole improves fat digestion and absorption in cystic fibrosis patients with residual faecal fat loss despite maximal pancreatic enzyme substitution." | 9.10 | Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. ( De Boeck, K; Proesmans, M, 2003) |
| " In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 9.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
| "We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22." | 9.07 | Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. ( Bakker, W; Heijerman, HG; Lamers, CB, 1991) |
| "The incidence of gastroesophageal reflux disease (GERD) is higher in patients with cystic fibrosis (CF) than in the general population." | 7.01 | Effect of omeprazole on symptoms of gastroesophageal reflux disease in children with cystic fibrosis. A randomized, double-blind, placebo-controlled trial. ( Banaszkiewicz, A; Dziekiewicz, M; Lisowska, A; Mielus, M; Radzikowski, A; Sands, D; Walkowiak, J, 2021) |
| " The large variability limited our ability to test for a difference in fat absorption and has significant implication for the use of this test, considered the gold standard, for determining enzyme dosage adequacy." | 6.70 | Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. ( Bowser, E; Francisco, MP; Novak, DA; Sherman, JM; Theriaque, D; Wagner, MH, 2002) |
| "Omeprazole improves fat digestion and absorption in cystic fibrosis patients with residual faecal fat loss despite maximal pancreatic enzyme substitution." | 5.10 | Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. ( De Boeck, K; Proesmans, M, 2003) |
| " In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 5.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
| "We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22." | 5.07 | Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. ( Bakker, W; Heijerman, HG; Lamers, CB, 1991) |
| "The incidence of gastroesophageal reflux disease (GERD) is higher in patients with cystic fibrosis (CF) than in the general population." | 3.01 | Effect of omeprazole on symptoms of gastroesophageal reflux disease in children with cystic fibrosis. A randomized, double-blind, placebo-controlled trial. ( Banaszkiewicz, A; Dziekiewicz, M; Lisowska, A; Mielus, M; Radzikowski, A; Sands, D; Walkowiak, J, 2021) |
| " The large variability limited our ability to test for a difference in fat absorption and has significant implication for the use of this test, considered the gold standard, for determining enzyme dosage adequacy." | 2.70 | Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. ( Bowser, E; Francisco, MP; Novak, DA; Sherman, JM; Theriaque, D; Wagner, MH, 2002) |
| "Pancreatic insufficiency is the second most important pathophysiological expression of cystic fibrosis (CF) and occurs in the majority of patients." | 2.38 | New modalities in the treatment of exocrine pancreatic insufficiency in cystic fibrosis. ( Heijerman, HG, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| Dziekiewicz, M | 1 |
| Mielus, M | 1 |
| Lisowska, A | 1 |
| Walkowiak, J | 1 |
| Sands, D | 1 |
| Radzikowski, A | 1 |
| Banaszkiewicz, A | 1 |
| Andrade, PHS | 1 |
| Lobo, IMF | 1 |
| da Silva, WB | 1 |
| Francisco, MP | 1 |
| Wagner, MH | 1 |
| Sherman, JM | 1 |
| Theriaque, D | 1 |
| Bowser, E | 1 |
| Novak, DA | 1 |
| Proesmans, M | 1 |
| De Boeck, K | 1 |
| Kaur, S | 1 |
| Norkina, O | 1 |
| Ziemer, D | 1 |
| Samuelson, LC | 1 |
| De Lisle, RC | 1 |
| Gan, KH | 1 |
| Heijerman, HG | 4 |
| Geus, WP | 1 |
| Bakker, W | 3 |
| Lamers, CB | 3 |
| Dijkman, JH | 1 |
| Barraclough, M | 1 |
| Taylor, CJ | 1 |
| Tran, TM | 1 |
| Van den Neucker, A | 1 |
| Hendriks, JJ | 2 |
| Forget, P | 1 |
| Forget, PP | 4 |
| Kester, AD | 1 |
| Donckerwolcke, R | 1 |
| Wouters, EF | 1 |
| Cuppoletti, J | 1 |
| Tewari, KP | 1 |
| Sherry, AM | 1 |
| Kupert, EY | 1 |
| Malinowska, DH | 1 |
| Hendriks, HJ | 2 |
| van Kreel, B | 1 |
| ter Heide, H | 1 |
| Heijmans, H | 1 |
| Menheere, PP | 1 |
| Spaapen, LJ | 1 |
| Bakker, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitors (PPI) and Fat Absorption in Subjects With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)[NCT03551691] | Phase 2 | 19 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for omeprazole and Cystic Fibrosis
| Article | Year |
|---|---|
New modalities in the treatment of exocrine pancreatic insufficiency in cystic fibrosis.
Topics: Cystic Fibrosis; Drug Therapy, Combination; Exocrine Pancreatic Insufficiency; Humans; Omeprazole; P | 1992 |
7 trials available for omeprazole and Cystic Fibrosis
| Article | Year |
|---|---|
Effect of omeprazole on symptoms of gastroesophageal reflux disease in children with cystic fibrosis. A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Gastroesophageal Reflux; | 2021 |
Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Cross-Over Studies; Cystic Fibrosis; Dietary Fats; Double-Blind Method; Fe | 2002 |
Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes.
Topics: Adolescent; Child; Child, Preschool; Cross-Over Studies; Cystic Fibrosis; Dose-Response Relationship | 2003 |
Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients.
Topics: Adult; Cystic Fibrosis; Feces; Female; Humans; Lipase; Lipid Metabolism; Male; Middle Aged; Nitrogen | 1994 |
Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas.
Topics: Adult; Cystic Fibrosis; Double-Blind Method; Feces; Female; Humans; Lipid Metabolism; Male; Omeprazo | 1993 |
Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adipose Tissue; Adolescent; Body Composition; Body Height; | 2001 |
Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis.
Topics: Adult; Capsules; Celiac Disease; Cystic Fibrosis; Double-Blind Method; Drug Interactions; Drug Thera | 1991 |
8 other studies available for omeprazole and Cystic Fibrosis
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Anesthesia, General; Anti-Bacterial Agents; Ant | 2017 |
Acidic duodenal pH alters gene expression in the cystic fibrosis mouse pancreas.
Topics: Acids; Amylases; Animals; Chimera; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula | 2004 |
Twenty-four hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic enzyme function and fat absorption.
Topics: Absorption; Acids; Child; Child, Preschool; Circadian Rhythm; Cystic Fibrosis; Dietary Fats; Duodenu | 1996 |
Effects of a proton-pump inhibitor in cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anthropometry; Celiac Disease; Child; Ch | 1998 |
ClC-2 Cl- channels in human lung epithelia: activation by arachidonic acid, amidation, and acid-activated omeprazole.
Topics: 1-Methyl-3-isobutylxanthine; Adenosine Triphosphate; Amides; Arachidonic Acids; Cell Line; Cells, Cu | 2001 |
Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Infective Agents; Biomarkers; Child; Child | 2001 |
Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Case-Control Studies; Child; Child, Preschool; | 2001 |